Present address: Laura Marroquí and Reinaldo S. Dos Santos, Cellular physiology and Nutrition Research Group, Bioengineering Institute, Miguel Hernández University, Elche, 03202, Spain; Spanish ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as ... and type 1 interferon. Alumis has already ...

When I want to fish, I throw my yak into the bed of my truck and go. The kayak always floats and my Old Town PDL drive always starts. I can also access water boats can’t reach, and if you factor in ...

Earlier this year, I was fortunate enough to be among the first people to test Old Town’s all-new 2025 Sportsman PDL 120 Pro. I can tell you with 100% honesty, it was one of the most memorable f ...

The company says the first readout from the CheckMate-915 trial showed the combination didn't improve on PD-1 inhibitor Opdivo (nivolumab) given on its own in patients with high-risk melanoma who ...

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland ...

ovarian cancer and PD-1/ PD-L1 drug-resistant solid tumors. LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two ...

Ruxolitinib and baricitinib are FDA-approved, orally bioavailable Jak 1/2 inhibitors that have been shown to indirectly decay the HIV-1 latent reservoir, and down-regulate markers of HIV-1 persistence ...

Background: Currently, there has been no direct comparison between programmed cell death protein 1 (PD-1) inhibitors plus different chemotherapy regimens in first-line treatments for advanced gastric ...